Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results

Pharmaceutical Investing

Inovio Pharmaceuticals (NASDAQ:INO) reported financial results for the fourth quarter and year ended December 31, 2017. As quoted in the press release: Total revenue was $8.8 million and $42.2 million for the quarter and year ended December 31, 2017, respectively, as compared to $8.5 million and $35.4 million for the same periods in 2016. Total …

Inovio Pharmaceuticals (NASDAQ:INO) reported financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

Total revenue was $8.8 million and $42.2 million for the quarter and year ended December 31, 2017, respectively, as compared to $8.5 million and $35.4 million for the same periods in 2016.

Total operating expenses for the quarter and year ended December 31, 2017 were $31.7 million and $125.9 million, respectively, as compared to $30.9 million and $111.6 million for the same periods in 2016.

The net loss attributable to common stockholders for the quarter and year ended December 31, 2017 was $21.5 million, or $0.24 per basic share, and $88.2 million, or $1.08 per basic share, respectively, as compared to a net loss attributable to common stockholders of $26.2 million, or $0.35 per basic share, and $73.7 million, or $1.01 per basic share, for the same periods in 2016.

Click here to read the full press release.

The Conversation (0)
Ă—